IONIS PHARMACEUTICALS INC

Ionis Pharmaceuticals slides 0.81% to $43.91 as investors weigh its RNA‑drug pipeline and market context amid cautious biotech sentiment.

Discover why Ionis Pharmaceuticals’ RNA‑targeted stock may be a hidden buying opportunity below its 200‑day average, with a promising Phase 2 pipeline and strategic partnerships poised for growth.

Ionis Pharmaceuticals’ FDA‑approved antisense drug Hibsago delivers a 20% functional cure rate for chronic hepatitis B, boosting its market position and shareholder upside.